Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on uniQure (QURE – Research Report) on March 28. The company’s shares closed last Tuesday at $17.80, close to its 52-week low of $14.29.
According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 35.0% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure with a $51.40 average price target, a 209.8% upside from current levels. In a report issued on March 17, UBS also upgraded the stock to Buy with a $40.00 price target.
uniQure’s market cap is currently $762.8M and has a P/E ratio of 2.30.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
- Emerson Electric Company (EMR) Gets a Hold Rating from Mizuho Securities
- Analysts Offer Insights on Healthcare Companies: Amarin (AMRN), Insmed (INSM) and MannKind (MNKD)
- TPG (TPG) Receives a Hold from Evercore ISI
- Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy Rating from Evercore ISI
- Robert W. Baird Keeps a Hold Rating on Progenity (PROG)